Vividion Therapeutics Inc. has synthesized RAS-PI3K inhibitors reported to be useful for the treatment of cancer and immunological disorders.

Suzhou Vigonvita Life Sciences Co. Ltd. has disclosed 5-HT1A receptor agonists reported to be useful for the treatment of neurological disorders.

Promis Neurosciences Inc. recently presented the rational design of an Alzheimer’s disease (AD) vaccine candidate maximizing the selective targeting of toxic amyloid-β oligomers.

Dravet syndrome (DS) is a rare and severe form of epilepsy that causes intellectual disability and motor deficits and can lead to premature death. A loss-of-function mutation in one copy of SCN1A, encoding the voltage-gated sodium channel (NaV)1.1 α subunit, is the most frequent alteration found in DS patients and has been linked with inhibitory neuron dysfunction. Despite the potential of gene therapies, AAV-mediated SCN1A gene replacement for DS has not been possible yet due to AAV genome size constraints.